Valuation: Autolus Therapeutics plc

Market Cap 423M 377M 349M 318M 596M 40.12B 606M 4.19B 1.65B 20.97B 1.59B 1.55B 67.04B P/E 2026 *
-1.95x
P/E 2027 * -2.28x
Enterprise Value 267M 238M 221M 201M 376M 25.33B 383M 2.65B 1.04B 13.24B 1B 981M 42.32B EV / Sales 2026 *
1.78x
EV / Sales 2027 * 1.8x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-0.63%
1 week-8.62%
Current month-18.04%
1 month-18.04%
3 months+10.42%
6 months-0.62%
Current year-20.10%
1 week 1.54
Extreme 1.54
1.74
1 month 1.54
Extreme 1.54
2.08
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2014-08-31
Chief Executive Officer 61 2016-02-29
Director of Finance/CFO 56 2023-08-06
Director TitleAgeSince
Chairman 61 2014-09-30
Director/Board Member 78 2014-07-31
Director/Board Member 71 2018-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Executive/Senior Manager

-6,713 0.0025%
6/29/26 Free

Director

79,167 0.0477%
3/18/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-0.62%-8.62%-1.85%-36.40% 426M
-1.33%+4.88%+54.50%+109.94% 1,120B
-0.69%-3.77%+31.35%+66.62% 616B
-0.96%+0.55%+23.13%+94.26% 504B
+0.24%+5.58%+33.98%+59.40% 367B
-1.59%-1.25%+69.39%+43.02% 360B
-0.40%+3.53%+19.17%+46.55% 288B
-0.37%+3.11%-1.26%+18.23% 258B
-1.75%+1.76%+42.21%+51.44% 234B
-2.00%+1.75%+24.64%+95.14% 194B
Average -0.95%+0.91%+29.53%+54.82% 394.13B
Weighted average by Cap. -0.99%+2.42%+37.89%+75.51%

Financials

2026 *2027 *
Net sales 150M 134M 124M 112M 211M 14.2B 214M 1.48B 583M 7.42B 562M 550M 23.73B 192M 172M 159M 144M 271M 18.24B 276M 1.91B 749M 9.53B 722M 707M 30.48B
Net income -221M -197M -182M -166M -311M -20.93B -316M -2.19B -860M -10.94B -828M -811M -34.98B -189M -168M -156M -142M -266M -17.88B -270M -1.87B -734M -9.35B -708M -693M -29.87B
Net Debt -156M -139M -129M -117M -220M -14.79B -223M -1.55B -608M -7.73B -585M -573M -24.72B -77.38M -68.97M -63.89M -58.09M -109M -7.34B -111M -766M -301M -3.83B -290M -284M -12.26B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
26-10-19 US$1.590 -0.63% 1,522,183
26-10-16 US$1.600 -6.98% 2,350,674
26-10-15 US$1.720 +1.78% 1,486,313
26-10-14 US$1.690 +4.32% 2,590,102
26-10-13 US$1.620 -6.90% 2,420,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.590USD
Average target price
8.725USD
Spread / Average Target
+448.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock